Sprog:
Valuta:

1 000 000 kunder har valgt vores fantastiske tjeneste og højkvalitets produkter

  • Spar op til 80%

    Store rabatter og tilbud

  • Hurtig & Verdensomspændende Levering

    Modtag bestillinger hurtigt

  • Intet behov for recept

    Køb piller uden begrænsninger

  • Tilfredshedsgaranti

    30-dages returret

Doctor
Din indkøbskurv er tom

Bekræftet apoteksudsalg

Mere end ethundrede godkendte attester

  • fda
  • fda
  • pgeu gpue
  • mipa
  • cipar
  • mastercard
  • visa
  • mcafee

Banners

Movfor

movfor
  • Movfor 200mg

    Forsendelse Pr Pille Specialpris
    200 kapsler Gratis Ekspreslevering $5.49 $1466 -26% Kun $1097
    160 kapsler Gratis Ekspreslevering $5.60 $1173 -24% Kun $896
    120 kapsler Gratis Ekspreslevering $5.79 $880 -21% Kun $695
    80 kapsler Gratis Ekspreslevering $6.18 $587 -16% Kun $494
    40 kapsler Gratis Almindelig Levering $7.33 Kun $293

Product Description

Common use
Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

Dosage and direction

Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days.
Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

Results

Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

Conclusions

Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

Du kan også lide:

Abonner Særlige tilbud og nyheder
Abonner

testimonials

    5 stars

Simone A “Jeg har aldrig i mit liv været lige så tilfreds med en online tjeneste. Forsendelsen sker hurtigt og tjenesten er let at bruge.”

Næste Anbefalinger